JP2013502429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502429A5 JP2013502429A5 JP2012525664A JP2012525664A JP2013502429A5 JP 2013502429 A5 JP2013502429 A5 JP 2013502429A5 JP 2012525664 A JP2012525664 A JP 2012525664A JP 2012525664 A JP2012525664 A JP 2012525664A JP 2013502429 A5 JP2013502429 A5 JP 2013502429A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- isoxazol
- acetamide
- amino
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 cyano, amino, hydroxy Chemical group 0.000 claims description 221
- 238000000034 method Methods 0.000 claims description 53
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 39
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 29
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- FPDVVQNKNNSRLM-UHFFFAOYSA-N [3-chloro-5-[4-[2-[[3-(3-methyloxetan-3-yl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=C(Cl)C([NH3+])=NC=2)ON=C1C1(C)COC1 FPDVVQNKNNSRLM-UHFFFAOYSA-N 0.000 claims description 3
- AGEUMEIHAWSGRB-UHFFFAOYSA-N [3-fluoro-5-[4-[2-[[3-(3-methyloxetan-3-yl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=C(F)C([NH3+])=NC=2)ON=C1C1(C)COC1 AGEUMEIHAWSGRB-UHFFFAOYSA-N 0.000 claims description 3
- IKDRSFWPIPAGNT-UHFFFAOYSA-N [5-[4-[2-[[3-(1-fluorocyclobutyl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium;acetate Chemical compound CC([O-])=O.C1=NC([NH3+])=CC=C1C(C=C1)=CC=C1CC(=O)NC1=CC(C2(F)CCC2)=NO1 IKDRSFWPIPAGNT-UHFFFAOYSA-N 0.000 claims description 3
- RKKQZFBAJHFZGY-UHFFFAOYSA-N [5-[4-[2-[[3-(2,2-difluoro-1-methylcyclopropyl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium;acetate Chemical compound CC([O-])=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)CC1(F)F RKKQZFBAJHFZGY-UHFFFAOYSA-N 0.000 claims description 3
- PRTSTZPQCQSCBN-UHFFFAOYSA-N [5-[4-[[3-(2,2-difluoro-1-methylcyclopropyl)-1,2-oxazol-5-yl]carbamoylamino]phenyl]pyridin-2-yl]azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)CC1(F)F PRTSTZPQCQSCBN-UHFFFAOYSA-N 0.000 claims description 3
- SFJLVUJTINFARG-UHFFFAOYSA-N methanesulfonate;[3-methyl-5-[4-[2-[[3-(3-methyloxetan-3-yl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.N1=C([NH3+])C(C)=CC(C=2C=CC(CC(=O)NC=3ON=C(C=3)C3(C)COC3)=CC=2)=C1 SFJLVUJTINFARG-UHFFFAOYSA-N 0.000 claims description 3
- UNTLQTVIPKUNEY-UHFFFAOYSA-N methanesulfonate;[5-[4-[2-[[3-(1-methylcyclobutyl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)CCC1 UNTLQTVIPKUNEY-UHFFFAOYSA-N 0.000 claims description 3
- GVGQXQNYLMDSJE-UHFFFAOYSA-N methanesulfonate;[5-[4-[2-[[3-(1-methylcyclopropyl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)CC1 GVGQXQNYLMDSJE-UHFFFAOYSA-N 0.000 claims description 3
- QVHUNFOFBXHTMW-UHFFFAOYSA-N methanesulfonate;[5-[4-[[3-(1-methylcyclopropyl)-1,2-oxazol-5-yl]carbamoylamino]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)CC1 QVHUNFOFBXHTMW-UHFFFAOYSA-N 0.000 claims description 3
- DCSZHAYOJIRJLI-UHFFFAOYSA-N methanesulfonate;[5-[4-[[3-[1-(trifluoromethyl)cyclobutyl]-1,2-oxazol-5-yl]carbamoylamino]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=NC([NH3+])=CC=C1C(C=C1)=CC=C1NC(=O)NC1=CC(C2(CCC2)C(F)(F)F)=NO1 DCSZHAYOJIRJLI-UHFFFAOYSA-N 0.000 claims description 3
- OCIHCSSBEQZYCO-UHFFFAOYSA-N [3-fluoro-5-[4-[2-[[3-(1-methylcyclopropyl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=C(F)C([NH3+])=NC=2)ON=C1C1(C)CC1 OCIHCSSBEQZYCO-UHFFFAOYSA-N 0.000 claims description 2
- LLERAPLNDGIZHE-UHFFFAOYSA-N methanesulfonate;[5-[4-[2-[[3-(3-methyloxetan-3-yl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]-3-(trifluoromethyl)pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=C(C([NH3+])=NC=2)C(F)(F)F)ON=C1C1(C)COC1 LLERAPLNDGIZHE-UHFFFAOYSA-N 0.000 claims description 2
- SUHXGCFMRUZQGI-UHFFFAOYSA-N methanesulfonate;[5-[4-[2-[[3-(3-methyloxetan-3-yl)-1,2-oxazol-5-yl]amino]-2-oxoethyl]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)CC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)COC1 SUHXGCFMRUZQGI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 89
- 125000005843 halogen group Chemical group 0.000 claims 56
- 125000000753 cycloalkyl group Chemical group 0.000 claims 47
- 125000001188 haloalkyl group Chemical group 0.000 claims 42
- 125000003342 alkenyl group Chemical group 0.000 claims 40
- 125000000304 alkynyl group Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- 125000003545 alkoxy group Chemical group 0.000 claims 38
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 36
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 21
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 19
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 3
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- RGTIEGZKUCTIQI-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-2-fluorophenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C(=CC(=CC=2)C=2C=NC(N)=CC=2)F)=N1 RGTIEGZKUCTIQI-UHFFFAOYSA-N 0.000 claims 2
- UATVAZZIRWDZJW-UHFFFAOYSA-N 2-[4-(6-amino-2-fluoropyridin-3-yl)phenyl]-n-[5-(1-methylcyclopropyl)-1,2-oxazol-3-yl]acetamide Chemical compound C=1C(NC(=O)CC=2C=CC(=CC=2)C=2C(=NC(N)=CC=2)F)=NOC=1C1(C)CC1 UATVAZZIRWDZJW-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- XMOCKPBLBBBAJX-UHFFFAOYSA-N [5-[4-[[3-(2-fluoropropan-2-yl)-1,2-oxazol-5-yl]carbamoylamino]phenyl]pyridin-2-yl]azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.O1N=C(C(C)(F)C)C=C1NC(=O)NC1=CC=C(C=2C=NC([NH3+])=CC=2)C=C1 XMOCKPBLBBBAJX-UHFFFAOYSA-N 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- KTAQMNBLMYYEAS-UHFFFAOYSA-N 1-(2-fluoro-5-methylphenyl)-3-[4-[2-(2-morpholin-4-ylethylamino)pyrimidin-5-yl]phenyl]urea Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=NC=2)=C1 KTAQMNBLMYYEAS-UHFFFAOYSA-N 0.000 claims 1
- LEZCBVQHLRKTMJ-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[2-fluoro-4-[6-(2-piperidin-1-ylethylamino)pyridin-3-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C(=CC(=CC=2)C=2C=NC(NCCN3CCCCC3)=CC=2)F)=N1 LEZCBVQHLRKTMJ-UHFFFAOYSA-N 0.000 claims 1
- NGNLGAMSLBPUIA-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(1,2,3,5-tetrahydropyrido[2,3-e][1,4]oxazepin-7-yl)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C3COCCNC3=NC=2)=N1 NGNLGAMSLBPUIA-UHFFFAOYSA-N 0.000 claims 1
- NRRJVZAUAVEQBB-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazin-7-yl)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C3OCCNC3=NC=2)=N1 NRRJVZAUAVEQBB-UHFFFAOYSA-N 0.000 claims 1
- MSRGLTKWJUZZNV-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(3-oxo-4h-pyrido[3,2-b][1,4]oxazin-7-yl)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C3OCC(=O)NC3=NC=2)=N1 MSRGLTKWJUZZNV-UHFFFAOYSA-N 0.000 claims 1
- KBYOYINAQFXNAF-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C3CCCNC3=NC=2)=N1 KBYOYINAQFXNAF-UHFFFAOYSA-N 0.000 claims 1
- GAZUXIRBXBWACN-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-(2-methoxyethylamino)pyrimidin-5-yl]phenyl]urea Chemical compound C1=NC(NCCOC)=NC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 GAZUXIRBXBWACN-UHFFFAOYSA-N 0.000 claims 1
- KNIVYSHNIIOYFC-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-(2-morpholin-4-ylethoxy)pyrimidin-5-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(OCCN3CCOCC3)=NC=2)=N1 KNIVYSHNIIOYFC-UHFFFAOYSA-N 0.000 claims 1
- XOMFKSVMGOXAIE-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-(2-morpholin-4-ylethylamino)pyrimidin-5-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=NC=2)=N1 XOMFKSVMGOXAIE-UHFFFAOYSA-N 0.000 claims 1
- DYZYDDOUBUBTQK-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-(2-piperidin-1-ylethylamino)pyrimidin-5-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCCCC3)=NC=2)=N1 DYZYDDOUBUBTQK-UHFFFAOYSA-N 0.000 claims 1
- LTZXBGLHIROMLC-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-(3-morpholin-4-ylpropyl)pyrimidin-5-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(CCCN3CCOCC3)=NC=2)=N1 LTZXBGLHIROMLC-UHFFFAOYSA-N 0.000 claims 1
- AAGGNJKQIKQHRZ-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-(morpholin-4-ylmethyl)pyrimidin-5-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(CN3CCOCC3)=NC=2)=N1 AAGGNJKQIKQHRZ-UHFFFAOYSA-N 0.000 claims 1
- UPATUIXPVLRHJN-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[2-[2-(dimethylamino)ethylamino]pyrimidin-5-yl]phenyl]urea Chemical compound C1=NC(NCCN(C)C)=NC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 UPATUIXPVLRHJN-UHFFFAOYSA-N 0.000 claims 1
- KNQQFXNBIFIPKB-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-cyano-6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C(C(NCCN3CCOCC3)=NC=2)C#N)=N1 KNQQFXNBIFIPKB-UHFFFAOYSA-N 0.000 claims 1
- WWIKKSQAXGYMGO-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=CC=2)=N1 WWIKKSQAXGYMGO-UHFFFAOYSA-N 0.000 claims 1
- VGULJDCUEBSQME-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(3-morpholin-4-ylpropylamino)pyridin-3-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCCN3CCOCC3)=CC=2)=N1 VGULJDCUEBSQME-UHFFFAOYSA-N 0.000 claims 1
- OFXMAYYQCCXYAL-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyridin-3-yl]phenyl]urea Chemical compound CN1CCCC1CCNC1=CC=C(C=2C=CC(NC(=O)NC3=NOC(=C3)C(C)(C)C)=CC=2)C=N1 OFXMAYYQCCXYAL-UHFFFAOYSA-N 0.000 claims 1
- CSFBAOXZJQXBBJ-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-[2-(4,4-difluoropiperidin-1-yl)ethylamino]pyridin-3-yl]phenyl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCC(F)(F)CC3)=CC=2)=N1 CSFBAOXZJQXBBJ-UHFFFAOYSA-N 0.000 claims 1
- DMPWOQSOJPXOBG-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[5-[2-(2-morpholin-4-ylethylamino)pyrimidin-5-yl]pyridin-2-yl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2N=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=NC=2)=N1 DMPWOQSOJPXOBG-UHFFFAOYSA-N 0.000 claims 1
- IEQWBUTYOGLBGK-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[5-[2-(cyclopropylamino)pyrimidin-5-yl]pyridin-2-yl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2N=CC(=CC=2)C=2C=NC(NC3CC3)=NC=2)=N1 IEQWBUTYOGLBGK-UHFFFAOYSA-N 0.000 claims 1
- QGPYNUUKSPTOFE-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[5-[2-(oxan-4-ylamino)pyrimidin-5-yl]pyridin-2-yl]urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2N=CC(=CC=2)C=2C=NC(NC3CCOCC3)=NC=2)=N1 QGPYNUUKSPTOFE-UHFFFAOYSA-N 0.000 claims 1
- BCTJHMLFSBSISN-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[5-[2-(propan-2-ylamino)pyrimidin-5-yl]pyridin-2-yl]urea Chemical compound C1=NC(NC(C)C)=NC=C1C(C=N1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 BCTJHMLFSBSISN-UHFFFAOYSA-N 0.000 claims 1
- YHFGRESZZUIFBR-UHFFFAOYSA-N 1-[3-(2-fluoropropan-2-yl)-1,2-oxazol-5-yl]-3-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]urea Chemical compound O1N=C(C(C)(F)C)C=C1NC(=O)NC1=CC=C(C=2C=NC(NCCN3CCOCC3)=CC=2)C=C1 YHFGRESZZUIFBR-UHFFFAOYSA-N 0.000 claims 1
- PNLBQQOEXGSXCW-UHFFFAOYSA-N 1-[4-(2-amino-4-methoxypyrimidin-5-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound COC1=NC(N)=NC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 PNLBQQOEXGSXCW-UHFFFAOYSA-N 0.000 claims 1
- DJKOWYRZGPYGFB-UHFFFAOYSA-N 1-[4-(2-amino-4-methylpyrimidin-5-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound CC1=NC(N)=NC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 DJKOWYRZGPYGFB-UHFFFAOYSA-N 0.000 claims 1
- WBSARNYAQLZHGW-UHFFFAOYSA-N 1-[4-(2-aminopyrimidin-5-yl)-2-methoxyphenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound COC1=CC(C=2C=NC(N)=NC=2)=CC=C1NC(=O)NC=1C=C(C(C)(C)C)ON=1 WBSARNYAQLZHGW-UHFFFAOYSA-N 0.000 claims 1
- JSVVHGVXWNWTHD-UHFFFAOYSA-N 1-[4-(2-aminopyrimidin-5-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=N1 JSVVHGVXWNWTHD-UHFFFAOYSA-N 0.000 claims 1
- DPKSRMNYQJZOIX-UHFFFAOYSA-N 1-[4-(6-amino-2-methylpyridin-3-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound CC1=NC(N)=CC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 DPKSRMNYQJZOIX-UHFFFAOYSA-N 0.000 claims 1
- URMISMUOOJRDOW-UHFFFAOYSA-N 1-[4-(6-amino-4-methylpyridin-3-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound CC1=CC(N)=NC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 URMISMUOOJRDOW-UHFFFAOYSA-N 0.000 claims 1
- SVDDIHFLQWZLQM-UHFFFAOYSA-N 1-[4-(6-amino-5-cyanopyridin-3-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C(C(N)=NC=2)C#N)=N1 SVDDIHFLQWZLQM-UHFFFAOYSA-N 0.000 claims 1
- BZKHHAIYZHTWBL-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-2,5-difluorophenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C(=CC(=C(F)C=2)C=2C=NC(N)=CC=2)F)=N1 BZKHHAIYZHTWBL-UHFFFAOYSA-N 0.000 claims 1
- ZBWWFLHMFCCVOI-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-2-chlorophenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C(=CC(=CC=2)C=2C=NC(N)=CC=2)Cl)=N1 ZBWWFLHMFCCVOI-UHFFFAOYSA-N 0.000 claims 1
- OTZYFDYDTDBFCK-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-2-methoxyphenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound COC1=CC(C=2C=NC(N)=CC=2)=CC=C1NC(=O)NC=1C=C(C(C)(C)C)ON=1 OTZYFDYDTDBFCK-UHFFFAOYSA-N 0.000 claims 1
- LSPHVBQDLABYNC-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-2-methoxyphenyl]-3-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound COC1=CC(C=2C=NC(N)=CC=2)=CC=C1NC(=O)NC=1C=C(C(C)(CF)CF)ON=1 LSPHVBQDLABYNC-UHFFFAOYSA-N 0.000 claims 1
- BKZBOFTXVYSLRI-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-3-chlorophenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(Cl)C(=CC=2)C=2C=NC(N)=CC=2)=N1 BKZBOFTXVYSLRI-UHFFFAOYSA-N 0.000 claims 1
- SQZJRLYCGJVIPJ-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)-3-fluorophenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=C(F)C(=CC=2)C=2C=NC(N)=CC=2)=N1 SQZJRLYCGJVIPJ-UHFFFAOYSA-N 0.000 claims 1
- ZRYOMQRSRSJWQS-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-(3-tert-butyl-1,2-oxazol-5-yl)urea Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=C1 ZRYOMQRSRSJWQS-UHFFFAOYSA-N 0.000 claims 1
- GSNCKMNQSBZDMN-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 GSNCKMNQSBZDMN-UHFFFAOYSA-N 0.000 claims 1
- HACGUALKEPTBQL-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[3-(1-fluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]urea Chemical compound O1N=C(C(C)(CF)C)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=C1 HACGUALKEPTBQL-UHFFFAOYSA-N 0.000 claims 1
- YKNMEWZWCHQHIA-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[3-(1-hydroxy-2-methylpropan-2-yl)-1,2-oxazol-5-yl]urea Chemical compound O1N=C(C(C)(CO)C)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=C1 YKNMEWZWCHQHIA-UHFFFAOYSA-N 0.000 claims 1
- YMJCTWSXSPMKCT-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[3-(2-fluoropropan-2-yl)-1,2-oxazol-5-yl]urea Chemical compound O1N=C(C(C)(F)C)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=C1 YMJCTWSXSPMKCT-UHFFFAOYSA-N 0.000 claims 1
- IQVMFLHGWGIGTB-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound O1C(C(C)(C)C(F)(F)F)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 IQVMFLHGWGIGTB-UHFFFAOYSA-N 0.000 claims 1
- QFLIUMCUTREBRL-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound O1C(C(CF)(CF)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 QFLIUMCUTREBRL-UHFFFAOYSA-N 0.000 claims 1
- SMLDDWYKBXMEQM-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea;methanesulfonic acid Chemical compound CS([O-])(=O)=O.O1C(C(CF)(CF)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC([NH3+])=CC=2)=N1 SMLDDWYKBXMEQM-UHFFFAOYSA-N 0.000 claims 1
- YGEOKXYIZANAEC-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1-fluoro-2-methylpropan-2-yl)-2-methylpyrazol-3-yl]urea Chemical compound CN1N=C(C(C)(C)CF)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=C1 YGEOKXYIZANAEC-UHFFFAOYSA-N 0.000 claims 1
- RXXYYRUVOVSTQP-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1-hydroxy-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound O1C(C(C)(CO)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 RXXYYRUVOVSTQP-UHFFFAOYSA-N 0.000 claims 1
- HYEMOOGRDSAUAP-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1-hydroxy-2-methylpropan-2-yl)-2-methylpyrazol-3-yl]urea Chemical compound CN1N=C(C(C)(C)CO)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=C1 HYEMOOGRDSAUAP-UHFFFAOYSA-N 0.000 claims 1
- AMESBBOUTCUTHT-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(1-methylcyclopropyl)-1,2-oxazol-3-yl]urea Chemical compound C=1C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=NOC=1C1(C)CC1 AMESBBOUTCUTHT-UHFFFAOYSA-N 0.000 claims 1
- LMEUMMIWBYYNBU-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(2,2-difluoro-1-methylcyclopropyl)-1,2-oxazol-3-yl]urea Chemical compound C=1C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=NOC=1C1(C)CC1(F)F LMEUMMIWBYYNBU-UHFFFAOYSA-N 0.000 claims 1
- YFMFIEKNDMNXEU-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-(3-methyloxetan-3-yl)-1,2-oxazol-3-yl]urea Chemical compound C=1C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=NOC=1C1(C)COC1 YFMFIEKNDMNXEU-UHFFFAOYSA-N 0.000 claims 1
- YEBLRVNCYZQNCY-UHFFFAOYSA-N 1-[4-(6-aminopyridin-3-yl)phenyl]-3-[5-[1-(trifluoromethyl)cyclobutyl]-1,2-oxazol-3-yl]urea Chemical compound C1=NC(N)=CC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C2(CCC2)C(F)(F)F)=C1 YEBLRVNCYZQNCY-UHFFFAOYSA-N 0.000 claims 1
- LVTPKICFLZUDDY-UHFFFAOYSA-N 1-[4-[2-(2-morpholin-4-ylethylamino)pyrimidin-5-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC(F)(F)C1=CC=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=NC=2)=C1 LVTPKICFLZUDDY-UHFFFAOYSA-N 0.000 claims 1
- BTLIICUQRGWTFR-UHFFFAOYSA-N 1-[4-[2-(2-morpholin-4-ylethylamino)pyrimidin-5-yl]phenyl]-3-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]urea Chemical compound C=1C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=NC=2)=NOC=1C1(C(F)(F)F)CC1 BTLIICUQRGWTFR-UHFFFAOYSA-N 0.000 claims 1
- LCVIRUIEJFYKTF-UHFFFAOYSA-N 1-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound O1C(C(C)(C)C(F)(F)F)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=CC=2)=N1 LCVIRUIEJFYKTF-UHFFFAOYSA-N 0.000 claims 1
- CGCYRDCQCQDKEO-UHFFFAOYSA-N 1-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]-3-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]urea Chemical compound C=1C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=CC=2)=NOC=1C1(C(F)(F)F)CC1 CGCYRDCQCQDKEO-UHFFFAOYSA-N 0.000 claims 1
- DDOCKAKRIHBJBF-UHFFFAOYSA-N 1-[4-[6-amino-5-(2-hydroxyethoxymethyl)pyridin-3-yl]phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C(COCCO)C(N)=NC=2)=N1 DDOCKAKRIHBJBF-UHFFFAOYSA-N 0.000 claims 1
- LJKMNRGZGDEEIJ-UHFFFAOYSA-N 1-[4-[6-amino-5-(hydroxymethyl)pyridin-3-yl]phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C(CO)C(N)=NC=2)=N1 LJKMNRGZGDEEIJ-UHFFFAOYSA-N 0.000 claims 1
- OVBIWYOCZZQYLE-UHFFFAOYSA-N 1-[4-[6-amino-5-(morpholin-4-ylmethyl)pyridin-3-yl]phenyl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=C(CN3CCOCC3)C(N)=NC=2)=N1 OVBIWYOCZZQYLE-UHFFFAOYSA-N 0.000 claims 1
- BHLFVHJTOYSLOF-UHFFFAOYSA-N 1-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]-3-[4-[2-(2-morpholin-4-ylethylamino)pyrimidin-5-yl]phenyl]urea Chemical compound O1C(C(CF)(CF)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=NC=2)=N1 BHLFVHJTOYSLOF-UHFFFAOYSA-N 0.000 claims 1
- DCJLSULENLGDOE-UHFFFAOYSA-N 1-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]-3-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]urea Chemical compound O1C(C(CF)(CF)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCCN3CCOCC3)=CC=2)=N1 DCJLSULENLGDOE-UHFFFAOYSA-N 0.000 claims 1
- NMMZDPCXOPXMPK-UHFFFAOYSA-N 1-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]-3-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]urea;methanesulfonic acid Chemical compound CS([O-])(=O)=O.O1C(C(CF)(CF)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCC[NH+]3CCOCC3)=CC=2)=N1 NMMZDPCXOPXMPK-UHFFFAOYSA-N 0.000 claims 1
- RDHBUROBXALHTJ-UHFFFAOYSA-N 1-[5-(6-amino-2-methylpyridin-3-yl)pyridin-2-yl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound CC1=NC(N)=CC=C1C(C=N1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 RDHBUROBXALHTJ-UHFFFAOYSA-N 0.000 claims 1
- HMMAHLCVEJAKNK-UHFFFAOYSA-N 1-[5-(6-amino-4-methylpyridin-3-yl)pyridin-2-yl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound CC1=CC(N)=NC=C1C(C=N1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 HMMAHLCVEJAKNK-UHFFFAOYSA-N 0.000 claims 1
- FTVIXYPCEKVGSE-UHFFFAOYSA-N 1-[5-(6-aminopyridin-3-yl)pyridin-2-yl]-3-[3-(2-fluoropropan-2-yl)-1,2-oxazol-5-yl]urea Chemical compound O1N=C(C(C)(F)C)C=C1NC(=O)NC1=CC=C(C=2C=NC(N)=CC=2)C=N1 FTVIXYPCEKVGSE-UHFFFAOYSA-N 0.000 claims 1
- WHMDJAGVAZXMMO-UHFFFAOYSA-N 1-[5-(6-aminopyridin-3-yl)pyridin-2-yl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound O1C(C(C)(C)C(F)(F)F)=CC(NC(=O)NC=2N=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 WHMDJAGVAZXMMO-UHFFFAOYSA-N 0.000 claims 1
- VTTACEGJSCWVRJ-UHFFFAOYSA-N 1-[5-(6-aminopyridin-3-yl)pyridin-2-yl]-3-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound O1C(C(CF)(CF)C)=CC(NC(=O)NC=2N=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 VTTACEGJSCWVRJ-UHFFFAOYSA-N 0.000 claims 1
- YTGDJBRVAJNFIA-UHFFFAOYSA-N 1-[5-(6-aminopyridin-3-yl)pyridin-2-yl]-3-[5-(1-methylcyclopropyl)-1,2-oxazol-3-yl]urea Chemical compound C=1C(NC(=O)NC=2N=CC(=CC=2)C=2C=NC(N)=CC=2)=NOC=1C1(C)CC1 YTGDJBRVAJNFIA-UHFFFAOYSA-N 0.000 claims 1
- YIDPUSGRSODVLE-UHFFFAOYSA-N 1-[5-(6-aminopyridin-3-yl)pyridin-2-yl]-3-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]urea Chemical compound C1=NC(N)=CC=C1C(C=N1)=CC=C1NC(=O)NC1=NOC(C2(CC2)C(F)(F)F)=C1 YIDPUSGRSODVLE-UHFFFAOYSA-N 0.000 claims 1
- AAVMTFFYANKDSQ-UHFFFAOYSA-N 1-[5-(6-aminopyridin-3-yl)thiophen-2-yl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2SC(=CC=2)C=2C=NC(N)=CC=2)=N1 AAVMTFFYANKDSQ-UHFFFAOYSA-N 0.000 claims 1
- SOLJUFJACWYSGZ-UHFFFAOYSA-N 1-[5-[2-(tert-butylamino)pyrimidin-5-yl]pyridin-2-yl]-3-(5-tert-butyl-1,2-oxazol-3-yl)urea Chemical compound C1=NC(NC(C)(C)C)=NC=C1C(C=N1)=CC=C1NC(=O)NC1=NOC(C(C)(C)C)=C1 SOLJUFJACWYSGZ-UHFFFAOYSA-N 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- LHQDHLJFVLYTFO-UHFFFAOYSA-N 2-[4-(6-amino-5-fluoropyridin-3-yl)phenyl]-n-[5-(1-methylcyclopropyl)-1,2-oxazol-3-yl]acetamide Chemical compound C=1C(NC(=O)CC=2C=CC(=CC=2)C=2C=C(F)C(N)=NC=2)=NOC=1C1(C)CC1 LHQDHLJFVLYTFO-UHFFFAOYSA-N 0.000 claims 1
- VHVBQGAXPDGWBO-UHFFFAOYSA-N 2-[4-(6-aminopyridin-3-yl)phenyl]-n-(5-tert-butyl-1,2-oxazol-3-yl)-2,2-difluoroacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(F)(F)C=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 VHVBQGAXPDGWBO-UHFFFAOYSA-N 0.000 claims 1
- YFQUWJXOXOUIQB-UHFFFAOYSA-N 2-[4-(6-aminopyridin-3-yl)phenyl]-n-(5-tert-butyl-1,2-oxazol-3-yl)-2-hydroxyacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(O)C=2C=CC(=CC=2)C=2C=NC(N)=CC=2)=N1 YFQUWJXOXOUIQB-UHFFFAOYSA-N 0.000 claims 1
- DRHLEUPIJBQGSY-UHFFFAOYSA-N 2-[4-(6-aminopyridin-3-yl)phenyl]-n-[3-(1-hydroxy-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide Chemical compound O1N=C(C(C)(CO)C)C=C1NC(=O)CC1=CC=C(C=2C=NC(N)=CC=2)C=C1 DRHLEUPIJBQGSY-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000007033 Dysgerminoma Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- NLIUFDAANCWZSF-UHFFFAOYSA-N N-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]acetamide Chemical compound CC(=O)Nc1cc(on1)C1(CC1)C(F)(F)F NLIUFDAANCWZSF-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- WSOQYGTWFRTYDI-UHFFFAOYSA-N methanesulfonate;1-[4-[6-(2-morpholin-4-ium-4-ylethylamino)pyridin-3-yl]phenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound CS([O-])(=O)=O.O1C(C(C)(C)C(F)(F)F)=CC(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCC[NH+]3CCOCC3)=CC=2)=N1 WSOQYGTWFRTYDI-UHFFFAOYSA-N 0.000 claims 1
- DPMNBHGNZUIZSZ-UHFFFAOYSA-N methanesulfonate;[5-[4-[[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]carbamoylamino]phenyl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=NC([NH3+])=CC=C1C(C=C1)=CC=C1NC(=O)NC1=NOC(C2(CC2)C(F)(F)F)=C1 DPMNBHGNZUIZSZ-UHFFFAOYSA-N 0.000 claims 1
- PTAIGGAQBKENIL-UHFFFAOYSA-N methanesulfonic acid;1-[4-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]phenyl]-3-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]urea Chemical compound CS([O-])(=O)=O.C=1C(NC(=O)NC=2C=CC(=CC=2)C=2C=NC(NCC[NH+]3CCOCC3)=CC=2)=NOC=1C1(C(F)(F)F)CC1 PTAIGGAQBKENIL-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- IVSPXHDALVJYAJ-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)acetamide Chemical compound CC(=O)NC=1C=C(C(C)(C)C)ON=1 IVSPXHDALVJYAJ-UHFFFAOYSA-N 0.000 claims 1
- GPYHDHZPFCJJSN-UHFFFAOYSA-N n-[4-(2-aminopyrimidin-5-yl)phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound C1=NC(N)=NC=C1C(C=C1)=CC=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 GPYHDHZPFCJJSN-UHFFFAOYSA-N 0.000 claims 1
- APUDMRNLSAWQHQ-UHFFFAOYSA-N n-[5-[2-(cyclopropylamino)pyrimidin-5-yl]pyridin-2-yl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)NC=2N=CC(=CC=2)C=2C=NC(NC3CC3)=NC=2)=C1 APUDMRNLSAWQHQ-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 40
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- IAXWZYXUKABJAN-UHFFFAOYSA-N 1,2-oxazol-5-amine Chemical compound NC1=CC=NO1 IAXWZYXUKABJAN-UHFFFAOYSA-N 0.000 description 3
- GFSGKPYPGLEOOI-UHFFFAOYSA-N 3-(1-methylcyclopropyl)-1,2-oxazol-5-amine Chemical compound C1=C(N)ON=C1C1(C)CC1 GFSGKPYPGLEOOI-UHFFFAOYSA-N 0.000 description 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 0 CC(*1)=CC=C1C1=C(*)N=C(**)**1 Chemical compound CC(*1)=CC=C1C1=C(*)N=C(**)**1 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- DPHGMMZSGLSBIA-UHFFFAOYSA-N phenyl n-[5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-yl]carbamate Chemical compound C=1C(NC(=O)OC=2C=CC=CC=2)=NOC=1C1(C(F)(F)F)CC1 DPHGMMZSGLSBIA-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- RYWGPCLTVXMMHO-UHFFFAOYSA-N (4-chlorophenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=C(Cl)C=C1 RYWGPCLTVXMMHO-UHFFFAOYSA-N 0.000 description 2
- NKTHMWBSTTUMNX-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CC(N)=O)C=C1 NKTHMWBSTTUMNX-UHFFFAOYSA-N 0.000 description 2
- GSPAKADVCIANQO-UHFFFAOYSA-N 3-(1-methylcyclopropyl)-3-oxopropanenitrile Chemical compound N#CCC(=O)C1(C)CC1 GSPAKADVCIANQO-UHFFFAOYSA-N 0.000 description 2
- VERBLYWQRHTUCK-UHFFFAOYSA-N 3-(2-fluoropropan-2-yl)-1,2-oxazol-5-amine Chemical compound CC(C)(F)C=1C=C(N)ON=1 VERBLYWQRHTUCK-UHFFFAOYSA-N 0.000 description 2
- NQXKTGUDJOMYCP-UHFFFAOYSA-N 3-[1-(trifluoromethyl)cyclobutyl]-1,2-oxazol-5-amine Chemical compound O1C(N)=CC(C2(CCC2)C(F)(F)F)=N1 NQXKTGUDJOMYCP-UHFFFAOYSA-N 0.000 description 2
- VDGYEPKGZAKXRP-UHFFFAOYSA-N 3-[1-(trifluoromethyl)cyclobutyl]-1,2-oxazole Chemical compound FC(C1(CCC1)C1=NOC=C1)(F)F VDGYEPKGZAKXRP-UHFFFAOYSA-N 0.000 description 2
- PMPZEEUNGQSAIQ-UHFFFAOYSA-N 3-methyloxetane-3-carboxylic acid Chemical compound OC(=O)C1(C)COC1 PMPZEEUNGQSAIQ-UHFFFAOYSA-N 0.000 description 2
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QLXASFJHUCKEHU-UHFFFAOYSA-N 5-bromo-3-fluoropyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1F QLXASFJHUCKEHU-UHFFFAOYSA-N 0.000 description 2
- LGSFUVUTZFDMEG-UHFFFAOYSA-N C1CC1(C2=NOC(=C2)N)C(F)F Chemical compound C1CC1(C2=NOC(=C2)N)C(F)F LGSFUVUTZFDMEG-UHFFFAOYSA-N 0.000 description 2
- CLLCVOKWUIDTGV-UHFFFAOYSA-N CC1(CC1(F)F)C2=NOC(=C2)N Chemical compound CC1(CC1(F)F)C2=NOC(=C2)N CLLCVOKWUIDTGV-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- GCZGQVRHZLOCDD-UHFFFAOYSA-N 1-methylcyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(C)CCC1 GCZGQVRHZLOCDD-UHFFFAOYSA-N 0.000 description 1
- HLFLYOQLHYYNLT-UHFFFAOYSA-N 2,2-difluoro-1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1(F)F HLFLYOQLHYYNLT-UHFFFAOYSA-N 0.000 description 1
- YCOAZGLRGGYBTB-UHFFFAOYSA-N 2-(3-amino-1,2-oxazol-5-yl)-2-methylpropan-1-ol Chemical compound OCC(C)(C)C1=CC(N)=NO1 YCOAZGLRGGYBTB-UHFFFAOYSA-N 0.000 description 1
- VQVBNWUUKLBHGI-UHFFFAOYSA-N 2-(4-bromophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Br)C=C1 VQVBNWUUKLBHGI-UHFFFAOYSA-N 0.000 description 1
- FNLWHBHWDXCWHV-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CC(O)=O)C=C1 FNLWHBHWDXCWHV-UHFFFAOYSA-N 0.000 description 1
- VVGISEBPNPXUKJ-UHFFFAOYSA-N 3-(1-methylcyclopropyl)-1,2-oxazole Chemical compound C1=CON=C1C1(C)CC1 VVGISEBPNPXUKJ-UHFFFAOYSA-N 0.000 description 1
- XOYSLYZLEDUURQ-UHFFFAOYSA-N 3-(3-methyloxetan-3-yl)-3-oxopropanenitrile Chemical compound N#CCC(=O)C1(C)COC1 XOYSLYZLEDUURQ-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- DAIWGUDPLIUWPT-UHFFFAOYSA-N 3-[1-(difluoromethyl)cyclopropyl]-3-oxopropanenitrile Chemical compound N#CCC(=O)C1(C(F)F)CC1 DAIWGUDPLIUWPT-UHFFFAOYSA-N 0.000 description 1
- APHNQOGPYLTSFX-UHFFFAOYSA-N 3-tert-butyl-1,2-oxazol-5-amine Chemical compound CC(C)(C)C=1C=C(N)ON=1 APHNQOGPYLTSFX-UHFFFAOYSA-N 0.000 description 1
- ZNBNBTIDJSKEAM-UHFFFAOYSA-N 4-[7-hydroxy-2-[5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic acid Chemical compound C1C(O)C(C)C(C(C)C(OC(=O)CC)C(C)C(O)=O)OC11OC(C)(C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CC1 ZNBNBTIDJSKEAM-UHFFFAOYSA-N 0.000 description 1
- CGEPRVBWGCYTOV-UHFFFAOYSA-N 4-fluoro-4-methyl-3-oxopentanenitrile Chemical compound CC(C)(F)C(=O)CC#N CGEPRVBWGCYTOV-UHFFFAOYSA-N 0.000 description 1
- DKFDPLVNPGJNDE-UHFFFAOYSA-N 4-pyridin-3-ylaniline Chemical compound C1=CC(N)=CC=C1C1=CC=CN=C1 DKFDPLVNPGJNDE-UHFFFAOYSA-N 0.000 description 1
- GWQWXJZWEMTWLH-UHFFFAOYSA-N 4-tert-butyl-1,2-oxazol-3-amine Chemical compound CC(C)(C)C1=CON=C1N GWQWXJZWEMTWLH-UHFFFAOYSA-N 0.000 description 1
- JGNFEBUORVOIOA-UHFFFAOYSA-N 5-(4-aminophenyl)-n-(2-morpholin-4-ylethyl)pyridin-2-amine Chemical compound C1=CC(N)=CC=C1C(C=N1)=CC=C1NCCN1CCOCC1 JGNFEBUORVOIOA-UHFFFAOYSA-N 0.000 description 1
- TZEDIKKTUBFPMF-UHFFFAOYSA-N 5-[1-(trifluoromethyl)cyclopropyl]-1,2-oxazol-3-amine Chemical compound O1N=C(N)C=C1C1(C(F)(F)F)CC1 TZEDIKKTUBFPMF-UHFFFAOYSA-N 0.000 description 1
- IJVQRWPXBNGDTA-UHFFFAOYSA-N 5-hydroxy-4,4-dimethyl-3-oxopentanenitrile Chemical compound OCC(C)(C)C(=O)CC#N IJVQRWPXBNGDTA-UHFFFAOYSA-N 0.000 description 1
- GGXGVZJHUKEJHO-UHFFFAOYSA-N 5-tert-butyl-1,2-oxazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NO1 GGXGVZJHUKEJHO-UHFFFAOYSA-N 0.000 description 1
- NWCWCLHTTWTDEE-UHFFFAOYSA-N CC1(CCC1)C2=NOC(=C2)N Chemical compound CC1(CCC1)C2=NOC(=C2)N NWCWCLHTTWTDEE-UHFFFAOYSA-N 0.000 description 1
- YBAXXLHEOQAQSR-UHFFFAOYSA-N CC1(COC1)C2=NOC(=C2)N Chemical compound CC1(COC1)C2=NOC(=C2)N YBAXXLHEOQAQSR-UHFFFAOYSA-N 0.000 description 1
- YZKNANMIOCCRHR-UHFFFAOYSA-O CC1(COC1)c1n[o]c(NC(Cc(cc2)ccc2-c2ccc([NH3+])nc2)=O)c1 Chemical compound CC1(COC1)c1n[o]c(NC(Cc(cc2)ccc2-c2ccc([NH3+])nc2)=O)c1 YZKNANMIOCCRHR-UHFFFAOYSA-O 0.000 description 1
- QTDGLKGKLXHUQX-UHFFFAOYSA-N CCCOCCc1n[o]c(NC(Cc(cc2)ccc2-c2cc(Cl)c(N)nc2)=O)c1 Chemical compound CCCOCCc1n[o]c(NC(Cc(cc2)ccc2-c2cc(Cl)c(N)nc2)=O)c1 QTDGLKGKLXHUQX-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- ORPJTITXUQKRPD-UHFFFAOYSA-N Cl.O1CCN(CC1)CCC=1C(=NC=CC1)N Chemical compound Cl.O1CCN(CC1)CCC=1C(=NC=CC1)N ORPJTITXUQKRPD-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- OYOLYRMBSFPXQR-UHFFFAOYSA-N Nc(nc1)ccc1-c1ccc(CC(Nc2cc(C3(CCC3)F)n[o]2)=O)cc1 Chemical compound Nc(nc1)ccc1-c1ccc(CC(Nc2cc(C3(CCC3)F)n[o]2)=O)cc1 OYOLYRMBSFPXQR-UHFFFAOYSA-N 0.000 description 1
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 description 1
- ODLGHYWGVJUDJA-UHFFFAOYSA-N benzyl 3-methyloxetane-3-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1(C)COC1 ODLGHYWGVJUDJA-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- PAILVKQSHRJIPE-UHFFFAOYSA-N ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(CO)CC1 PAILVKQSHRJIPE-UHFFFAOYSA-N 0.000 description 1
- AYUISFJYNKIHDD-UHFFFAOYSA-N ethyl 1-(trifluoromethyl)cyclobutane-1-carboxylate Chemical compound CCOC(=O)C1(C(F)(F)F)CCC1 AYUISFJYNKIHDD-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000378 hydroxylammonium sulfate Inorganic materials 0.000 description 1
- JUBPGJYIBFWMRQ-UHFFFAOYSA-N methanesulfonate;(5-pyridin-3-ylpyridin-2-yl)azanium Chemical compound CS([O-])(=O)=O.C1=NC([NH3+])=CC=C1C1=CC=CN=C1 JUBPGJYIBFWMRQ-UHFFFAOYSA-N 0.000 description 1
- RJFLCPPGIDQAHC-UHFFFAOYSA-N methanesulfonate;[5-[6-[[3-(1-methylcyclopropyl)-1,2-oxazol-5-yl]carbamoylamino]pyridin-3-yl]pyridin-2-yl]azanium Chemical compound CS([O-])(=O)=O.C1=C(NC(=O)NC=2N=CC(=CC=2)C=2C=NC([NH3+])=CC=2)ON=C1C1(C)CC1 RJFLCPPGIDQAHC-UHFFFAOYSA-N 0.000 description 1
- OEGBOFOVYSOERL-UHFFFAOYSA-N methyl 2-fluoro-2-methylpropanoate Chemical compound COC(=O)C(C)(C)F OEGBOFOVYSOERL-UHFFFAOYSA-N 0.000 description 1
- ZVXAFVCHEIPHDR-UHFFFAOYSA-N methyl 3,3,3-trifluoro-2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C(F)(F)F ZVXAFVCHEIPHDR-UHFFFAOYSA-N 0.000 description 1
- IFFNDNZRDKTJEH-UHFFFAOYSA-N methyl 3-fluoro-2-(fluoromethyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(CF)CF IFFNDNZRDKTJEH-UHFFFAOYSA-N 0.000 description 1
- KJRFTNVYOAGTHK-UHFFFAOYSA-N methyl 3-hydroxy-2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)CO KJRFTNVYOAGTHK-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KDJWLVDAZBRXOD-UHFFFAOYSA-N phenyl n-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]carbamate Chemical compound O1C(C(C)(C)C(F)(F)F)=CC(NC(=O)OC=2C=CC=CC=2)=N1 KDJWLVDAZBRXOD-UHFFFAOYSA-N 0.000 description 1
- JDQCLNBTRQPLGY-UHFFFAOYSA-N phenyl n-[5-(1,3-difluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]carbamate Chemical compound O1C(C(CF)(CF)C)=CC(NC(=O)OC=2C=CC=CC=2)=N1 JDQCLNBTRQPLGY-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23531609P | 2009-08-19 | 2009-08-19 | |
| US61/235,316 | 2009-08-19 | ||
| PCT/US2010/045876 WO2011022473A1 (en) | 2009-08-19 | 2010-08-18 | Biaryl compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013502429A JP2013502429A (ja) | 2013-01-24 |
| JP2013502429A5 true JP2013502429A5 (enExample) | 2013-10-03 |
Family
ID=43033281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525664A Pending JP2013502429A (ja) | 2009-08-19 | 2010-08-18 | ビアリール化合物及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130035326A1 (enExample) |
| EP (1) | EP2467137A1 (enExample) |
| JP (1) | JP2013502429A (enExample) |
| KR (1) | KR20120059558A (enExample) |
| CN (1) | CN102470127A (enExample) |
| BR (1) | BR112012003661A2 (enExample) |
| CA (1) | CA2770454A1 (enExample) |
| MX (1) | MX2012001974A (enExample) |
| WO (1) | WO2011022473A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651930B1 (en) * | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| MY173181A (en) | 2011-05-13 | 2020-01-02 | Array Biopharma Inc | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| US8877763B2 (en) * | 2012-03-22 | 2014-11-04 | Genosco | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
| KR101529496B1 (ko) * | 2012-12-27 | 2015-06-22 | 한국과학기술원 | 낮은 열팽창 계수를 갖는 신규한 폴리아미드이미드 |
| AU2014229233B2 (en) * | 2013-03-15 | 2016-08-11 | Glaxosmithkline Intellectual Property Development Limited | Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors |
| AR095308A1 (es) | 2013-03-15 | 2015-10-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento |
| EP3039021A1 (en) * | 2013-08-30 | 2016-07-06 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
| CN104513252B (zh) * | 2013-09-26 | 2017-11-10 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| CN104513253A (zh) | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| PT3466955T (pt) | 2014-01-13 | 2021-01-29 | Aurigene Discovery Tech Ltd | Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro |
| US20170283404A1 (en) * | 2014-09-08 | 2017-10-05 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
| MX381233B (es) | 2014-09-10 | 2025-03-12 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret). |
| RS58813B1 (sr) | 2014-09-10 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
| CN105461709B (zh) * | 2014-09-26 | 2020-01-21 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| CN104387331A (zh) * | 2014-10-27 | 2015-03-04 | 湖南华腾制药有限公司 | 一种吡嗪衍生物的制备方法 |
| CN105001172B (zh) * | 2015-06-30 | 2018-02-09 | 浙江大学 | 5,6‑二取代氮杂嘧啶酮类化合物及制备方法 |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| ES2904615T3 (es) | 2016-03-16 | 2022-04-05 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones al respecto |
| JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| AU2018242623B2 (en) * | 2017-03-31 | 2024-05-02 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| EP3720436A4 (en) * | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | TUBULIN INHIBITORS |
| MX2020006587A (es) | 2017-12-22 | 2020-12-10 | Ravenna Pharmaceuticals Inc | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
| CN111741944B (zh) * | 2018-02-01 | 2025-01-03 | 悉尼大学 | 抗癌化合物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| WO2021144360A1 (en) * | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
| DK4146348T3 (da) | 2020-05-08 | 2024-09-30 | Halia Therapeutics Inc | Inhibitorer af nek7-kinase |
| CN111840285A (zh) * | 2020-06-10 | 2020-10-30 | 苏州安康盟医疗科技有限公司 | Gpr17和/或csfr1受体抑制剂 |
| US20240116962A1 (en) * | 2020-12-31 | 2024-04-11 | Tsinghua University | Pyridine-2-amine derivative and pharmaceutical composition and use thereof |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| WO2022236255A2 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3209472C2 (de) | 1982-03-16 | 1984-05-17 | Degussa Ag, 6000 Frankfurt | Verfahren zur Herstellung von 3-Oxonitrilen sowie neue 3-Oxonitrile |
| ZA834032B (en) * | 1982-06-05 | 1984-04-25 | Smith Kline French Lab | Heterocyclic compounds |
| US4657906A (en) * | 1982-06-05 | 1987-04-14 | Smith Kline & French Laboratories Ltd. | Heterocyclic compounds having inotropic activity |
| EP0096517A3 (en) * | 1982-06-05 | 1985-04-03 | Smith Kline & French Laboratories Limited | Aryl pyrazinones |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| JPS6296479A (ja) | 1985-10-23 | 1987-05-02 | Shionogi & Co Ltd | ポリフルオロアルキルイソオキサゾリルアミン類 |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| AU722289B2 (en) | 1996-10-01 | 2000-07-27 | Aptalis Pharmatech, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| ES2154253T3 (es) * | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
| CA2316273A1 (en) | 1998-01-16 | 1999-07-22 | Takeda Chemical Industries, Ltd. | Sustained-release composition, method of its production and use thereof |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| GEP20053476B (en) * | 1999-08-12 | 2005-03-25 | Upjohn Co | 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents |
| CA2458029A1 (en) * | 2001-09-13 | 2003-03-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
| DE10201764A1 (de) * | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7112435B1 (en) | 2002-08-07 | 2006-09-26 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| DE10219294A1 (de) * | 2002-04-25 | 2003-11-13 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| CN1826324B (zh) * | 2003-05-22 | 2011-12-07 | 雅培制药有限公司 | 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂 |
| GB0413955D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| US7709645B2 (en) * | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| TW200800201A (en) | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| CA2632476A1 (en) | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
| AR059197A1 (es) | 2006-01-25 | 2008-03-19 | Smithkline Beecham Corp | Derivados de indazolo piridina para el tratamiento de hiv |
| RU2008141761A (ru) * | 2006-03-22 | 2010-04-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ |
| WO2008005310A2 (en) | 2006-06-30 | 2008-01-10 | Ambit Biosciences Corp. | Detectable nucleic acid tag |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| WO2009011285A1 (ja) * | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | ヘテロアリールベンゼン化合物 |
| EA020317B1 (ru) * | 2008-05-23 | 2014-10-30 | УАЙТ ЭлЭлСи | ТРИАЗИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ PI3 И mTOR |
-
2010
- 2010-08-18 BR BR112012003661A patent/BR112012003661A2/pt not_active IP Right Cessation
- 2010-08-18 JP JP2012525664A patent/JP2013502429A/ja active Pending
- 2010-08-18 CN CN2010800366234A patent/CN102470127A/zh active Pending
- 2010-08-18 EP EP10745711A patent/EP2467137A1/en not_active Withdrawn
- 2010-08-18 WO PCT/US2010/045876 patent/WO2011022473A1/en not_active Ceased
- 2010-08-18 US US13/390,911 patent/US20130035326A1/en not_active Abandoned
- 2010-08-18 KR KR1020127007076A patent/KR20120059558A/ko not_active Withdrawn
- 2010-08-18 MX MX2012001974A patent/MX2012001974A/es not_active Application Discontinuation
- 2010-08-18 CA CA2770454A patent/CA2770454A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502429A5 (enExample) | ||
| JP7592814B2 (ja) | Ｃｆｔｒ増強物質としてのピロロピリミジン | |
| AU2023270195B2 (en) | 2,3-dihydroquinazolin compounds as NAV1.8 inhibitors | |
| JP7088983B2 (ja) | キナーゼ阻害剤としてのビアリールアミド化合物 | |
| JP7688578B2 (ja) | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 | |
| US10501436B2 (en) | Compounds and methods of use | |
| CA2647819C (en) | Phenylcyclohexyl derivatives as dgat1 inhibitors | |
| CA2702647C (en) | Thiopyrimidine-based compounds and uses thereof | |
| AU2005304393B2 (en) | IL-12 modulatory compounds | |
| JP6923543B2 (ja) | Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール | |
| CA3104131A1 (en) | Inhibitors of cyclin-dependent kinases | |
| JP2010503701A (ja) | 増殖性疾患の治療に有用なキナーゼ阻害剤 | |
| IL294052B1 (en) | Fluoroalkyl-oxadiazoles and uses thereof | |
| CA2938855C (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| CA3020478A1 (en) | Thiazolopyridine derivatives as gpr119 agonists | |
| CA3118934A1 (en) | Pyridazinone compounds and uses thereof | |
| EA015488B1 (ru) | Содержащие диариловый эфир соединения мочевины | |
| JP2022526890A (ja) | 化合物及びその使用 | |
| SG175640A1 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| JP2016504289A (ja) | がん治療用のピリミジン−２，４−ジアミン誘導体 | |
| US10392404B2 (en) | Compounds and compositions as kinase inhibitors | |
| CA2968633A1 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| CA2988637A1 (en) | Aromatic sulfonamide derivatives | |
| US10954232B2 (en) | Pyrazole derivative as ALK5 inhibitor and uses thereof | |
| TW202118759A (zh) | 用於治療癌症之１，２，４—二唑—５—酮衍生物 |